Patritumab deruxtecan in HER2-negative breast cancer: part B results of the window-of-opportunity SOLTI-1805 TOT-HER3 trial and biological determinants of early response
Patritumab deruxtecan治疗HER2阴性乳腺癌:SOLTI-1805 TOT-HER3机会窗口试验的B部分结果及早期反应的生物学决定因素
期刊:Nature Communications
影响因子:15.7
doi:10.1038/s41467-024-50056-y
Brasó-Maristany, Fara; Ferrero-Cafiero, Juan Manuel; Falato, Claudette; Martínez-Sáez, Olga; Cejalvo, Juan Miguel; Margelí, Mireia; Tolosa, Pablo; Salvador-Bofill, Francisco Javier; Cruz, Josefina; González-Farré, Blanca; Sanfeliu, Esther; Òdena, Andreu; Serra, Violeta; Pardo, Francisco; Luna Barrera, Ana María; Arumi, Miriam; Guerra, Juan Antonio; Villacampa, Guillermo; Sánchez-Bayona, Rodrigo; Ciruelos, Eva; Espinosa-Bravo, Martín; Izarzugaza, Yann; Galván, Patricia; Matito, Judith; Pernas, Sonia; Vidal, Maria; Santhanagopal, Anu; Sellami, Dalila; Esker, Stephen; Fan, Pang-Dian; Suto, Fumitaka; Vivancos, Ana; Pascual, Tomás; Prat, Aleix; Oliveira, Mafalda